Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Harvard Business School
Baxter
AstraZeneca
McKinsey

Last Updated: June 28, 2022

XERESE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Xerese patents expire, and what generic alternatives are available?

Xerese is a drug marketed by Bausch and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-five patent family members in twenty-one countries.

The generic ingredient in XERESE is acyclovir; hydrocortisone. There are fifty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acyclovir; hydrocortisone profile page.

DrugPatentWatch® Generic Entry Outlook for Xerese

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 13, 2022. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for XERESE
International Patents:25
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 1
Formulation / Manufacturing:see details
Drug Prices: Drug price information for XERESE
What excipients (inactive ingredients) are in XERESE?XERESE excipients list
DailyMed Link:XERESE at DailyMed
Drug patent expirations by year for XERESE
Drug Prices for XERESE

See drug prices for XERESE

DrugPatentWatch® Estimated Generic Entry Opportunity Date for XERESE
Generic Entry Date for XERESE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CREAM;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XERESE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Meda PharmaceuticalsPhase 3
TKL Research, Inc.Phase 3

See all XERESE clinical trials

US Patents and Regulatory Information for XERESE

XERESE is protected by two US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of XERESE is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting XERESE

Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)

Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch XERESE acyclovir; hydrocortisone CREAM;TOPICAL 022436-001 Jul 31, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for XERESE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch XERESE acyclovir; hydrocortisone CREAM;TOPICAL 022436-001 Jul 31, 2009 See Plans and Pricing See Plans and Pricing
Bausch XERESE acyclovir; hydrocortisone CREAM;TOPICAL 022436-001 Jul 31, 2009 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for XERESE

See the table below for patents covering XERESE around the world.

Country Patent Number Title Estimated Expiration
Algeria 1966 Combinaison pharmaceutique nouvelle. See Plans and Pricing
Turkey 9801439 See Plans and Pricing
Japan 4260220 See Plans and Pricing
Morocco 23800 See Plans and Pricing
China 1131034 See Plans and Pricing
Yugoslavia 7296 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for XERESE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0809498 SPC/GB10/012 United Kingdom See Plans and Pricing PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0809498 10C0038 France See Plans and Pricing PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
0809498 CA 2010 00009 Denmark See Plans and Pricing
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Medtronic
Merck
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.